| Cyril M Joseph, PA-C | |
|
1470 E Calvada Blvd Ste 600, Pahrump, NV 89048-3906 | |
| (775) 727-9800 | |
| (775) 727-9928 |
| Full Name | Cyril M Joseph |
|---|---|
| Gender | Male |
| Speciality | Physician Assistant |
| Experience | 12 Years |
| Location | 1470 E Calvada Blvd Ste 600, Pahrump, Nevada |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1912349408 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | PA1448 (Nevada) | Secondary |
| 363A00000X | Physician Assistant | PA1448 (Nevada) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Daniel Taheri Md Pc | 8325142334 | 8 |
News Archive
New research has found that one of the world's most prolific bacteria manages to afflict humans, animals and even plants by way of a mechanism not before seen in any infectious microorganism - a sense of touch. This unique ability helps make the bacteria Pseudomonas aeruginosa ubiquitous, but it also might leave these antibiotic-resistant organisms vulnerable to a new form of treatment.
Late-breaking data from the landmark HORIZONS-AMI clinical trial, presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, demonstrated that after two years, in heart attack patients, the use of a drug-eluting stent (paclitaxel) was safer and more effective than a bare-metal stent; and that the administration of the anticoagulant medication bivalirudin enhanced safety and efficacy compared to the use of heparin + GPIIb/IIIa inhibitors.
A new study by researchers at the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH) published in JAMA concludes that obesity kills 112,000 Americans each year - a dramatic decrease from an admittedly flawed study published last year by the CDC.
Researchers from the University of Bern, Inselspital, Bern University Hospital and the Swiss Center for Electronics and Microtechnology develop a high-precision, sensor-based surgical robot for spinal operations together with industry partners.
Pivotal Therapeutics Inc., a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, is pleased to announce that VASCAZEN met its primary endpoint in the REVEAL trial.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Cyril M Joseph, PA-C 2409 Artesia Blvd Fl 2, Redondo Beach, CA 90278-3207 Ph: () - | Cyril M Joseph, PA-C 1470 E Calvada Blvd Ste 600, Pahrump, NV 89048-3906 Ph: (775) 727-9800 |
News Archive
New research has found that one of the world's most prolific bacteria manages to afflict humans, animals and even plants by way of a mechanism not before seen in any infectious microorganism - a sense of touch. This unique ability helps make the bacteria Pseudomonas aeruginosa ubiquitous, but it also might leave these antibiotic-resistant organisms vulnerable to a new form of treatment.
Late-breaking data from the landmark HORIZONS-AMI clinical trial, presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, demonstrated that after two years, in heart attack patients, the use of a drug-eluting stent (paclitaxel) was safer and more effective than a bare-metal stent; and that the administration of the anticoagulant medication bivalirudin enhanced safety and efficacy compared to the use of heparin + GPIIb/IIIa inhibitors.
A new study by researchers at the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH) published in JAMA concludes that obesity kills 112,000 Americans each year - a dramatic decrease from an admittedly flawed study published last year by the CDC.
Researchers from the University of Bern, Inselspital, Bern University Hospital and the Swiss Center for Electronics and Microtechnology develop a high-precision, sensor-based surgical robot for spinal operations together with industry partners.
Pivotal Therapeutics Inc., a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, is pleased to announce that VASCAZEN met its primary endpoint in the REVEAL trial.
› Verified 4 days ago